We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+56.31%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.28B
AUM Growth
+$186M
Cap. Flow
+$21.2M
Cap. Flow %
0.93%
Top 10 Hldgs %
55.42%
Holding
67
New
19
Increased
9
Reduced
10
Closed
10

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$49.9M
2
TRML
Tourmaline Bio
TRML
+$44.1M
3
CGON icon
CG Oncology
CGON
+$32.7M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$30.4M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$30.4M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$160M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$75.4M
3
IMVT icon
Immunovant
IMVT
+$49.1M
4
CBAY
Cymabay Therapeutics
CBAY
+$42.5M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.56B
$427M 18.72%
8,494,151
– –
EYPT icon
2
EyePoint Inc
EYPT
$999M
$142M 6.25%
6,893,235
+855,000
+14% +$21.2M
ACLX
3
DELISTED
Arcellx
ACLX
$124M 5.43%
1,780,000
+80,000
+5% +$5.07M
ALPN
4
DELISTED
Alpine Immune Sciences Inc
ALPN
$107M 4.69%
2,700,000
+150,000
+6% +$4.43M
BBIO icon
5
BridgeBio Pharma
BBIO
$16.4B
$99M 4.34%
3,203,029
-141,150
-4% -$4.8M
PRAX icon
6
Praxis Precision Medicines
PRAX
$8.11B
$79.9M 3.51%
1,310,000
+676,655
+107% +$30.4M
CRBP icon
7
Corbus Pharmaceuticals
CRBP
$165M
$79.5M 3.49%
+2,025,000
New +$49.9M
TARS icon
8
Tarsus Pharmaceuticals
TARS
$2.55B
$77.8M 3.41%
2,139,102
-82,320
-4% -$2.42M
LBPH
9
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$72.4M 3.18%
3,353,141
+1,000,000
+42% +$21.8M
EWTX icon
10
Edgewise Therapeutics
EWTX
$4.28B
$54.8M 2.41%
3,006,534
+454,545
+18% +$7.22M
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$8.88B
$53.8M 2.36%
1,150,000
– –
BMEA icon
12
Biomea Fusion
BMEA
$88.2M
$53.4M 2.34%
3,570,872
– –
KRRO icon
13
Korro Bio
KRRO
$145M
$47.6M 2.09%
529,170
– –
PCVX icon
14
Vaxcyte
PCVX
$7.65B
$46.8M 2.05%
685,000
+20,000
+3% +$1.38M
AUTL
15
Autolus Therapeutics
AUTL
$389M
$42.2M 1.85%
6,616,667
+1,166,667
+21% +$7.28M
PHVS icon
16
Pharvaris
PHVS
$2.28B
$39.6M 1.74%
1,711,460
– –
NAMS icon
17
NewAmsterdam Pharma
NAMS
$3.26B
$35.5M 1.56%
+1,500,000
New +$30.4M
CGON icon
18
CG Oncology
CGON
$6.1B
$35.1M 1.54%
+800,000
New +$32.7M
ALXO icon
19
ALX Oncology
ALXO
$262M
$35M 1.54%
3,142,079
– –
BHVN icon
20
Biohaven
BHVN
$2.02B
$33.7M 1.48%
616,963
+535,000
+653% +$26.5M
MRUS
21
DELISTED
Merus
MRUS
$32.2M 1.41%
+715,000
New +$29M
JBIO
22
Jade Biosciences
JBIO
$1.18B
$31.6M 1.39%
30,566
-4,054
-12% -$3.1M
ABVX
23
Abivax
ABVX
$10.4B
$30.5M 1.34%
2,130,000
– –
BBOT
24
BridgeBio Oncology
BBOT
$659M
$30.3M 1.33%
+2,909,000
New +$30.1M
MRNS
25
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$29.4M 1.29%
3,250,000
– –
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Cormorant Asset Management held 67 positions worth $2.28B, up 8.9% from $2.09B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Cormorant Asset Management's Q1 2024 filing shows 19 new, 9 increased, 10 reduced and 10 closed positions. Its largest new stake was Corbus Pharmaceuticals: 2,025,000 shares worth $79.5M. The largest sale was Ambrx Biopharma Inc, an estimated $160M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

  • Cormorant Asset Management's largest Q1 2024 buy was Corbus Pharmaceuticals: 2,025,000 shares worth $79.5M.
  • Cormorant Asset Management added most to Praxis Precision Medicines in Q1 2024, an estimated $30.4M increase.
  • Cormorant Asset Management's biggest Q1 2024 reduction was Spyre Therapeutics, cutting an estimated $19.9M.
  • Cormorant Asset Management fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $160M.
  • Cormorant Asset Management's ten largest holdings make up 55% of its $2.28B portfolio in Q1 2024.
  • Cormorant Asset Management opened 19 new positions and closed 10 in Q1 2024.
  • Cormorant Asset Management's portfolio value rose 8.9% quarter-over-quarter to $2.28B.

Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.